Table of Contents
Advances in Endocrinology
Volume 2015, Article ID 782530, 6 pages
http://dx.doi.org/10.1155/2015/782530
Research Article

Effects of Low-Dose Pioglitazone on Serum Levels of Adiponectin, Dehydroepiandrosterone, Amyloid Beta Peptide, and Lipid Profile in Elderly Japanese People with Type 2 Diabetes

National Hospital Organization, Matsumoto Medical Center, Matsumoto Hospital, Matsumoto 399-8701, Japan

Received 31 August 2015; Revised 4 October 2015; Accepted 7 October 2015

Academic Editor: Curtis Triplitt

Copyright © 2015 Yuji Aoki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, vol. 38, no. 1, pp. 140–149, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Levin, S. Bell, R. Sund et al., “Pioglitazone and bladder cancer risk: amultipopulation pooled, cumulative exposure analysis,” Diabetologia, vol. 58, no. 3, pp. 493–504, 2015. View at Publisher · View at Google Scholar
  3. J. D. Lewis, L. A. Habel, C. P. Quesenberry et al., “Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes,” The Journal of the American Medical Association, vol. 314, no. 3, pp. 265–277, 2015. View at Publisher · View at Google Scholar
  4. T. Majima, Y. Komatsu, K. Doi et al., “Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus,” Endocrine Journal, vol. 53, no. 3, pp. 325–330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Aso, K. Hara, N. Ozeki et al., “Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 85, no. 2, pp. 147–152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Kato, Y. Sawai, H. Kanayama et al., “Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome,” Experimental and Clinical Endocrinology & Diabetes, vol. 117, no. 10, pp. 593–599, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Kurisu, T. Iwasaki, K. Ishibashi et al., “Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 14, no. 1, pp. 51–55, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Rajagopalan, P. Dutta, D. Hota, A. Bhansali, A. Srinivasan, and A. Chakrabarti, “Effect of low dose pioglitazone on glycemic control and insulin resistance in Type 2 diabetes: a randomized, double blind, clinical trial,” Diabetes Research and Clinical Practice, vol. 109, no. 3, pp. e32–e35, 2015. View at Publisher · View at Google Scholar
  9. T. Nakamura, E. Yamamoto, K. Kataoka et al., “Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure,” Stroke, vol. 38, no. 11, pp. 3016–3022, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Araki and T. Nishikawa, “Oxidative stress: a cause and therapeutic target of diabetic complications,” Journal of Diabetes Investigation, vol. 1, no. 3, pp. 90–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. E. Toblli, G. Cao, J. F. Giani, M. Angerosa, F. P. Dominici, and N. F. Gonzalez-Cadavid, “Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis,” Kidney and Blood Pressure Research, vol. 34, no. 1, pp. 20–33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. C. R. Swanson, V. Joers, V. Bondarenko et al., “The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys,” Journal of Neuroinflammation, vol. 8, article 91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. Q.-Q. Yin, J.-J. Pei, S. Xu et al., “Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats,” PLoS ONE, vol. 8, no. 3, Article ID e59313, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. D. G. Crenshaw, K. Asin, W. K. Gottschalk, Z. Liang, N. Zhang, and A. D. Roses, “Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain,” PLoS ONE, vol. 10, no. 2, Article ID e0117973, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Arai and N. Hirose, “Adiponectin and healthy aging in centenarians,” Anti-Aging Medicine, vol. 9, no. 1, pp. 1–5, 2012. View at Publisher · View at Google Scholar
  16. N. E. Gulcelik, M. Haul, S. Ariogul, and A. Usman, “Adipocytokines and aging: adiponectin and leptin,” Minerva Endocrinologica, vol. 38, no. 2, pp. 203–210, 2013. View at Google Scholar · View at Scopus
  17. S. S. C. Yen, “Dehydroepiandrosterone sulfate and longevity: new clues for an old friend,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8167–8169, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Sanders, R. M. Boudreau, A. R. Cappola et al., “Cardiovascular disease is associated with greater incident dehydroepiandrosterone sulfate decline in the oldest old: the cardiovascular health study all stars study,” Journal of the American Geriatrics Society, vol. 58, no. 3, pp. 421–426, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. A. Luis, L. Abdullah, D. Paris et al., “Serum β-amyloid correlates with neuropsychological impairment,” Aging, Neuropsychology, and Cognition, vol. 16, no. 2, pp. 203–218, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Ruiz, P. Pesini, A. Espinosa et al., “Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates,” PLoS ONE, vol. 8, no. 11, Article ID e81334, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Ito, M. Fujimura, M. Ohta, and T. Hirano, “Development of a homogeneous assay for measurement of small dense LDL cholesterol,” Clinical Chemistry, vol. 57, no. 1, pp. 57–65, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. R. C. Hoogeveen, J. W. Gaubatz, W. Sun et al., “Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 5, pp. 1069–1077, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Whelan, “(n-6) and (n-3) polyunsaturated fatty acids and the aging brain: food for thought,” Journal of Nutrition, vol. 138, no. 12, pp. 2521–2522, 2008. View at Publisher · View at Google Scholar
  24. R. J. Deckelbaum, “n-6 and n-3 Fatty acids and atherosclerosis: ratios or amounts?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 12, pp. 2325–2326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Fujita, Y. Yamada, M. Kusama et al., “Sex differences in the pharmacokinetics of pioglitazone in rats,” Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, vol. 136, no. 1, pp. 85–94, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Aronoff, S. Rosenblatt, S. Braithwaite, J. W. Egan, A. L. Mathisen, and R. L. Schneider, “Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study,” Diabetes Care, vol. 23, no. 11, pp. 1605–1611, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tobe, “Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1784–1792, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. P. O. Szapary, L. T. Bloedon, F. F. Samaha et al., “Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 1, pp. 182–188, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Qin, T. Liu, V. S. Kamanna, and M. L. Kashyap, “Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-α,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 11, pp. 2428–2434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Winkler, T. Konrad, S. Füllert et al., “Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study,” Diabetes Care, vol. 26, no. 9, pp. 2588–2594, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. U. N. Das, “A defect in Δ6 and Δ5 desaturases may be a factor in the initiation and progression of insulin resistance, the metabolic syndrome and ischemic heart disease in South Asians,” Lipids in Health and Disease, vol. 9, article 130, 2010. View at Publisher · View at Google Scholar
  32. J. Whelan, “(n-6) and (n-3) polyunsaturated fatty acids and the aging brain: food for thought,” Journal of Nutrition, vol. 138, no. 12, pp. 2521–2522, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. J. H. Moon, H. J. Kim, A. H. Yang et al., “The effect of rosiglitazone on LRP1 expression and amyloid β uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment,” International Journal of Neuropsychopharmacology, vol. 15, no. 1, pp. 135–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. N. S. Shah, J.-S. Vidal, K. Masaki et al., “Midlife blood pressure, plasma β-amyloid, and the risk for alzheimer disease: the honolulu asia aging study,” Hypertension, vol. 59, no. 4, pp. 780–786, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Kempná, G. Hofer, P. E. Mullis, and C. E. Flück, “Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2,” Molecular Pharmacology, vol. 71, no. 3, pp. 787–798, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. K. S. Nair, R. A. Rizza, P. O'Brien et al., “DHEA in elderly women and DHEA or testosterone in elderly men,” The New England Journal of Medicine, vol. 355, no. 16, pp. 1647–1659, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Kanazawa, T. Yamaguchi, and T. Sugimoto, “Effects of intensive glycemic control on serum levels of insulin-like growth factor-I and dehydroepiandrosterone sulfate in Type 2 diabetes mellitus,” Journal of Endocrinological Investigation, vol. 35, no. 5, pp. 469–472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Wilcox, M.-G. Bousser, D. J. Betteridge et al., “Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04),” Stroke, vol. 38, no. 3, pp. 865–873, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. S. E. Nissen, S. J. Nicholls, K. Wolski et al., “Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial,” Journal of the American Medical Association, vol. 299, no. 13, pp. 1561–1573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Jafari, B. Khodayari, J. Felgner, I. I. Bussel, M. R. Rose, and L. D. Mueller, “Pioglitazone: an anti-diabetic compound with anti-aging properties,” Biogerontology, vol. 8, no. 6, pp. 639–651, 2007. View at Publisher · View at Google Scholar · View at Scopus